Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 |
| clinicaltrials |
| NCT00846612 | Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | completed | Phase 1 | 15 | NYU Langone HealthOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02178670 | Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02849353 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02520115 | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | completed | Phase 1 | 50 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT02179970 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers(CAM-PLEX) | completed | Phase 1 | 26 | CCTU- Cancer ThemeOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04029909 | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | unknown | Phase 1 | 12 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 113 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02530047 | Mesenchymal Stem Cells (MSC) for Ovarian Cancer | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01281514 | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | completed | Phase 1 | 21 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | completed | Phase 1 / Phase 2 | 9 | AdaptimmuneINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT02575651 | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | completed | Phase 1 | 79 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00357448 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | completed | Phase 1 | 11 | University of WashingtonOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT00862355 | Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 98 | Verastem, Inc.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03916679 | MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT03895788 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | unknown | Phase 1 | 24 | Hunan Cancer HospitalOTHER | 1 | Mar 29, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00003002 | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | completed | Phase 1 | 60 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03011320 | An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery | completed | Phase 1 | 3 | EndocyteINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT00002600 | Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03551171 | The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | completed | Phase 1 | 42 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02582931 | MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT02418624 | Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer(REVIVAL) | completed | Phase 1 | 25 | The Netherlands Cancer InstituteOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT02950064 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | unknown | Phase 1 | 95 | Placon TherapeuticsINDUSTRY | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | PfizerINDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02539719 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | terminated | Phase 1 | 74 | StemcentrxINDUSTRY | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03763123 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | unknown | Phase 1 | 48 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 18, 2019source: clinicaltrials